Site #001
Dallas, Texas, 75247, United States
NCT Number: NCT02663999
This is a single-center, two-period, randomized, open-label, crossover pharmacokinetic (PK) study in healthy adult volunteers to evaluate dose proportionality of diazepam nasal spray using two dose levels
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 1
Dallas, Texas, 75247, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
diazepam nasal spray at two dose levels (DL). One dose of diazepam nasal spray is administered as two intranasal sprays; one in each nostril using a nasal spray device.
Other names: PLUMIAZ™ (diazepam) Nasal Spray
Time frame: within 15 minutes prior to dosing and at specified time points up to 24 hours post-dose
Time frame: within 15 minutes prior to dosing and at specified time points up to 24 hours post-dose
Time frame: within 15 minutes prior to dosing and at specified time points up to 24 hours post-dose
Time frame: within 15 minutes prior to dosing and at specified time points up to 24 hours post-dose
Time frame: up to 21 days
Time frame: within 30 minutes prior to dosing and at specified time points up to 24 hours post-dose
Time frame: from 5 minutes up to 24 hours post-dose
If patient reports a change in taste associated with diazepam nasal spray, questionnaire to be completed by research staff.
Acorda Therapeutics
Industry
A Two-Period, Randomized, Open-Label, Crossover Pharmacokinetic Study to Assess Dose Proportionality, Safety and Tolerability of Diazepam Nasal Spray in Healthy Adult Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details